In vitro characterization of a sustained-release formulation for enfuvirtide

Antimicrobial Agents and Chemotherapy
Sam N RothsteinSteven R Little

Abstract

Although approved by the U.S. Food and Drug Administration, enfuvirtide is rarely used in combination antiretroviral therapies (cART) to treat HIV-1 infection, primarily because of its intense dosing schedule that requires twice-daily subcutaneous injection. Here, we describe the development of enfuvirtide-loaded, degradable poly(lactic-co-glycolic) acid microparticles that provide linear in vitro release of the drug over an 18-day period. This sustained-release formulation could make enfuvirtide more attractive for use in cART.

Citations

Sep 12, 2019·Journal of Applied Toxicology : JAT·Kirt R PhippsPascale Fança-Berthon
Jul 27, 2018·Frontiers of Medicine·Rui ShiWei Tian

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Related Papers

Expert Opinion on Pharmacotherapy
Véronique JolyPatrick Yeni
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
David A WheelerMiklos Salgo
The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG
Jennifer L Morris, Donna M Kraus
© 2021 Meta ULC. All rights reserved